Studying cellular fats reveals how to protect cells from the common cold
As temperatures drop and the sniffles start, take hope; research published this summer suggests a new approach to protect ourselves from the common cold. By analysing changes to the make-up and types of cellular fat molecules in cells as they are infected by the cold virus, the research identified three chemicals that point to those that could be developed into a new type of anti-cold drug that could actually stop the infection in its tracks.
The Babraham Institute research, led by Professor Michael Wakelam, Director of the Institute, used a technique called lipidomics to examine the many different fat molecules, called lipids, which are found in all cells. By partnering with scientists at the National Heart and Lung Institute at Imperial College London, the researchers identified 493 changes to the lipids within human cells as they are being infected by the cold virus.
The team have used these insights to select inhibitors that can prevent key changes to the lipid makeup of cells. This reduced virus replication and therefore limited further infection by the cold virus.
Statistics on cold infections are hard to come by, but an adult typically gets between four and six colds per year. In total these viruses account for around 4 in 10 sick days from work.
Colds are caused by viruses which need to enter our cells and hijack their biological systems. The hijacked cells make more viruses and eventually die releasing the viruses to infect other cells and spread between people. Cold viruses typically attack cells in the nose, throat and lungs and our body’s response to this is what causes all the classic cold symptoms.
Current research focuses on a virus called rhinovirus, the most common cause of colds; causing between 30 - 80% of cases. There are around 160 different rhinoviruses that cause colds in humans, this study focuses on one, called RV-A1b, but the team believe that the same approach could easily be applied to other viruses too.
Fat molecules (lipids) are essential components of all cells with as many as 20,000 distinct fat molecules in our cells. One of their most important uses is to form the outer membrane of each cell as well as the membranes that encase different parts of cells.
Certain lipids also play an important role in how cells organise themselves and respond to their surroundings through lipid-based signalling systems. As such, lipids are a complex and varied part of cells but their significance in health and disease has often been overlooked. The hope is that lipid analysis may provide new insights into the treatment of a range of previously untreatable diseases, including the common cold.
The paper’s first author, An Nguyen, a member of the Signalling research programme at the Babraham Institute, said: “Our results show an unexpected and remarkable complexity of lipid changes in response to rhinovirus infection. We found changes in both the types of lipids found in cells as well as in the length and structure of the fatty acid chains that are a critical part of all lipid molecules. These discoveries have helped us to identify key pathways that represent potential anti-viral drug targets and have demonstrated the potential of lipidomics as a means to discover new treatments.”
This research was supported by funding from BBSRC and MRC.
Notes to editors
About the Babraham Institute
The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC) through an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.
Tags: news health pharmaceuticals human health The Babraham Institute